AtG Therapeutics is a recently created spin-off from IDIBELL and ICO, announces its launch with a first round of financing collecting 556,000 euros, received the support of international and national entities, including Blue Goose Capital, Women Angels for STEAM (WA4STEAM), the StapleCat/Inveniam group, and renowned international scientists.
AtG Therapeutics has been founded by researchers Oriol Casanovas and Gabriela Jiménez, with international advisor Bart Huisken, AtG Therapeutics will develop a portfolio of drugs for advanced cancer treatment. The company has a team with extensive consolidated experience in the pharmaceutical and biotechnology industry.
The company is progressing on two programs; a drug focused on a new therapeutic target
involved in the metabolism of tumor cells and a patient selector that will allow the
identification of those patients who will benefit from the treatment. Respectively, AtG 153
is already in the preclinical validation, and AngioDxPredict is in the prototype development
phase. The initial portfolio will serve as the basis for further expansion into the future
development of innovative R&D programs for various oncology indications.
"With a portfolio initially focused on three advanced cancers, kidney, colorectal, and breast
cancer, we do not doubt that AtG will create significant value for patients and in an industry
with an existing market opportunity," notes Blue Goose Capital, Boston (MA).
"AtG Therapeutics fits perfectly with the requirements of the projects in which we want to
invest clear STEAM innovation, a female entrepreneur in the founding team, a competent
and committed team, and a well-designed project meeting a well-defined market need",
WA4STEAM points out.
“We are proud to announce the launch of AtG Therapeutics -says Dr. Gabriela Jiménez, co-
founder and CEO of the spin-off-. The high-quality assets in our product portfolio will
potentially change the lives of patients without effective therapeutic alternatives."
"It is very motivating and exciting to see how the work of so many years of research is
already reaching a stage where it will soon become a reality for patients with advanced
cancer and will help them fight this disease," says Dr. Oriol Casanovas co-founder and CSO
of AtG Therapeutics.
"We have contributed to the creation of AtG to accelerate the advances of Dr. Casanovas'
research group focused on the development of therapies based on precision medicine to help
patients with advanced cancers," adds Dr. Gabriel Capellá, director of IDIBELL
About AtG Therapeutics
AtG Therapeutics is a recently created spinoff from IDIBELL and ICO. This project was supported by various
international and national institutions, including the European Research Council (ERC), the "La Caixa"
Foundation, the Spanish Association Against Cancer, the Carlos III Health Institute, and La Prospectiva en Salud en Spain (FIPSE). www.atgtx.com
About Blue Goose Capital
Blue Goose Capital is a Boston-based investment fund that invests in early-stage to Series B
biopharmaceutical, data, and device companies in the US and Spain. https://bluegoosecap.com/
About WA4STEAM
WA4STEAM is a growing international community of women angel investors seeking to expand women
entrepreneurial presence in the STEAM fields. https://wa4steam.com/
cloud technology axon
tuTECHÔ, empresa social que lucha contra el sinhogarismo en España, ...
